Speaker
George Scangos, PhD, ARCH Venture Partners, Boston, MA, United States
How Evidence, Pricing, and Policy Now Play a Role in Biotech Value
The biotech investment landscape is entering a new cycle—one defined not just by breakthrough science, but by the ability to convert innovation into sustainable, real-world value. Drawing on decades of experience building and leading companies at Exelixis, Biogen, Vir Biotechnology, and now at ARCH Venture Partners, Dr. Scangos will offer a candid assessment of what distinguishes tomorrow’s biotech winners from the rest.
In this keynote, Dr. Scangos will explore how evidence strategy, pricing discipline, and policy awareness have become central drivers of enterprise value, shaping everything from capital allocation to exit outcomes. He will explore traditional assumptions about risk, scale, and access, and highlight the strategic decisions investors and leaders must get right—earlier than ever—to succeed in today’s evolving healthcare landscape